TRIPLEX, NCT05223647: Chemo-immunotherapy Plus Thoracic Radiotherapy in Extensive Stage Small-cell Lung Cancer |
|
|
| Recruiting | 3 | 302 | Europe, RoW | Thoracic radiotherapy, Chemo-immunotherapy, carboplatin/etoposide/durvalumab | Norwegian University of Science and Technology, St. Olavs Hospital, Haukeland University Hospital, University Hospital of North Norway, Alesund Hospital, Helse Stavanger HF, Oslo University Hospital, Helse Nord-Trøndelag HF, Helse Fonna, Drammen sykehus, University Hospital, Akershus, Erasmus Medical Center, Sahlgrenska University Hospital, Sweden, Karolinska University Hospital, Gävle Hospital, Sykehuset Innlandet HF, North Estonia Medical Centre, Nordlandssykehuset HF, Landspitali University Hospital, Lund University Hospital, University Hospital, Linkoeping | Small-cell Lung Cancer | 01/26 | 10/29 | | |
| Active, not recruiting | 2 | 100 | Europe | Durvalumab Injection, Imfinzi | Oslo University Hospital, AstraZeneca | Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Stage III, NSCLC, NSCLC, Stage III | 05/25 | 05/33 | | |
